Organization: Inex Pharmaceuticals Corp

Inex inks deal with Alnylam for RNAi

Vancouver’s Inex Pharmaceuticals Corp has granted an exclusive worldwide license to Alnylam Pharmaceuticals Inc, Cambridge MA, for its liposomal delivery formulation technology for the commercialization of RNA Interference (RNAi) therapeutics. Inex will receive US$8 million in Alnylam cash or stock at Anlylam’s option and three InterfeRx licence options to develop RNAi therapeutics. In addition, Anlylam…

Inex co-development deal with Enzon terminated

A development and commercialization agreement between Inex Pharmaceuticals Corp, Vancouver, and Enzon Pharmaceuticals Inc, Bridgewater NJ, has been terminated following the decision of the FDA to issue a “not approvable” letter for Inex’s leading anti-cancer drug, Marqibo. Inex received a final $5-million payment from Enzon and is seeking new investment. The collaboration with Enzon lasted…

DRDC licenses anti-anthrax technology to Aradigm

Defence R&D Canada (DRDC) has entered into an $2.9-million deal with Hayward CA-based Aradigm Corp to develop an aerosol delivery mechanism for liposomal-encapsulated ciproflaxicin for the treatment of respiratory infections caused by anthrax and other biological agents. The agreement will see DRDC fund Aradigm’s product and formulation development and initial pre-clinical studies, building on DRDC’s…

Inex cuts workforce, reduces burn rate

Inex Pharmaceuticals Corp, Vancouver, is slashing its workforce and cutting back on its planned pipeline activities following the rejection by US regulatory authorities of its application for accelerated approval of Marqibo, the firm’s lead anticancer drug. The Oncology Drugs Advisory Committee of the US Food and Drug Administration voted unanimously against accelerated approval for Marqibo,…

Inex strikes lucrative collaboration agreement

Burnaby BC-based Inex Pharmaceuticals Corp has entered a strategic partnership with Enzon Pharmaceuticals Inc, Bridgewater NJ, for the development and commercialization of its Onco TCS oncology drug. Inex will receive US$12 million up front and an additional US$20 million when it receives FDA approval for its rolling new drug application, expected this spring. Further milestone…